NGM Biopharmaceuticals, Inc.

NasdaqGS:NGM Stock Report

Mkt Cap: US$426.6m

NGM Biopharmaceuticals Future Growth

How is NGM Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


4.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGS:NGM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202519-172-55-474
12/31/202417-148-67-606
12/31/202327-142-87-905
9/30/202258-153-134-132N/A
6/30/202269-135-115-114N/A
3/31/202277-125-89-87N/A
12/31/202178-120-75-73N/A
9/30/202177-121-77-75N/A
6/30/202182-122-93-91N/A
3/31/202185-111-88-87N/A
12/31/202087-102-85-83N/A
9/30/202099-90-81-78N/A
6/30/202097-72-62-60N/A
3/31/2020102-54-50-48N/A
12/31/2019104-43-45-41N/A
9/30/2019120-13-22-20N/A
6/30/2019119-9-22-19N/A
3/31/2019116-5-22-15N/A
12/31/20181090-13-8N/A
9/30/201881-17-24-18N/A
6/30/201880-12-22-15N/A
3/31/201877-13-21-16N/A
12/31/201777-14-24-17N/A
12/31/201686-7-241N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NGM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NGM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NGM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NGM's revenue (15.3% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: NGM's revenue (15.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NGM's Return on Equity is forecast to be high in 3 years time


Discover growth companies